Your browser doesn't support javascript.
loading
Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients with oily skin.
Tanghetti, Emil A; Zeichner, Joshua A; Gold, Michael; Sadick, Neil; Cook-Bolden, Fran E; Kircik, Leon H; Stein Gold, Linda; Weiss, Jonathan; Tyring, Stephen K; Del Rosso, James Q; Guenin, Eric.
Afiliación
  • Tanghetti EA; Center for Dermatology and Laser Surgery, Sacramento, CA, USA.
  • Zeichner JA; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Gold M; Tennessee Clinical Research Center, Nashville, TN, USA.
  • Sadick N; Department of Dermatology, Weill Cornell Medical College, New York, NY, USA.
  • Cook-Bolden FE; Sadick Dermatology, New York, NY, USA.
  • Kircik LH; Department of Dermatology, Weill Cornell Medical College, New York, NY, USA.
  • Stein Gold L; Fran E. Cook-Bolden, MD, PLLC, New York, NY, USA.
  • Weiss J; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Tyring SK; Department of Dermatology, Indiana University Medical Center, Indianapolis, IN, USA.
  • Del Rosso JQ; Physicians Skin Care, PLLC, DermResearch, PLLC, and Skin Sciences, PLLC, Louisville, KY, USA.
  • Guenin E; Department of Dermatology, Henry Ford Hospital, Detroit, MI, USA.
J Dermatolog Treat ; 34(1): 2147391, 2023 Dec.
Article en En | MEDLINE | ID: mdl-36382987
BACKGROUND: Excessive sebum production is a factor in acne development. Tazarotene 0.045% lotion has demonstrated reductions in acne lesions and acne-induced sequelae. OBJECTIVE: Evaluate efficacy, changes in skin oiliness, and safety with tazarotene 0.045% lotion in participants with moderate-to-severe acne and oily skin. METHODS: In two phase 3, double-blind, 12-week studies (NCT03168321; NCT03168334), participants aged ≥ 9 years with moderate-to-severe acne were randomized 1:1 to once-daily tazarotene 0.045% lotion or vehicle lotion (N = 1614). This pooled, post hoc analysis included only participants self-categorized with oily skin at baseline on the Acne-Specific Quality of Life questionnaire item 19 (scores: 0 [extremely oily] to 6 [not at all oily]). Inflammatory/noninflammatory lesion counts, treatment success, skin oiliness, treatment-emergent adverse events (TEAEs), and cutaneous safety/tolerability were evaluated. RESULTS: In all participants with oily skin (n = 793), tazarotene provided greater reductions in inflammatory/noninflammatory lesions (p < 0.001, both) and greater treatment success rates versus vehicle (p < 0.01) at week 12. Over two-thirds of polymeric lotion-treated participants had subjective skin oiliness reductions by week 12, with around a third reporting 'low/not' oily skin. Tazarotene TEAE rates were similar to the overall population. CONCLUSIONS: Once-daily treatment with tazarotene 0.045% polymeric emulsion lotion may help improve patient-perceived skin oiliness in those with moderate-to-severe acne.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Acné Vulgar / Fármacos Dermatológicos Tipo de estudio: Clinical_trials Aspecto: Patient_preference Límite: Humans Idioma: En Revista: J Dermatolog Treat Asunto de la revista: DERMATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Acné Vulgar / Fármacos Dermatológicos Tipo de estudio: Clinical_trials Aspecto: Patient_preference Límite: Humans Idioma: En Revista: J Dermatolog Treat Asunto de la revista: DERMATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido